Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?

2012 ◽  
Vol 12 (10) ◽  
pp. 1173-1176 ◽  
Author(s):  
Stefaan Van Gool ◽  
Steven De Vleeschouwer
Keyword(s):  
Dendritic Cell ◽  
Standard Therapy ◽  
Newly Diagnosed ◽  
Tumor Vaccination ◽  
Newly Diagnosed Glioblastoma

scholarly journals OS2.5 Long term remission/survival over 8 years in patients with newly diagnosed glioblastoma (GBM) treated with ICT-107 dendritic cell-based immunotherapy (phase I)

2016 ◽  
Vol 18 (suppl_4) ◽  
pp. iv5-iv5 ◽  
Author(s):  
S. Phuphanich ◽  
C. Wheeler ◽  
J. Rudnick ◽  
J. Hu ◽  
M. Mazer ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Phase I ◽  
Newly Diagnosed ◽  
Newly Diagnosed Glioblastoma

scholarly journals ATIM-13. ALLOGENEIC TUMOR LYSATE/AUTOLOGOUS DENDRITIC CELL VACCINES IN NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS OF CLINICAL TRIAL MC1272

2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi28-vi29 ◽  
Author(s):  
Ian F Parney ◽  
Michael P Gustafson ◽  
Timothy Peterson ◽  
Susan M Steinmetz ◽  
Allan B Dietz
Keyword(s):  
Clinical Trial ◽  
Dendritic Cell ◽  
Newly Diagnosed ◽  
Autologous Dendritic Cell ◽  
Tumor Lysate ◽  
Allogeneic Tumor ◽  
Dendritic Cell Vaccines ◽  
Newly Diagnosed Glioblastoma

scholarly journals Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

2012 ◽  
Vol 62 (1) ◽  
pp. 125-135 ◽  
Author(s):  
Surasak Phuphanich ◽  
Christopher J. Wheeler ◽  
Jeremy D. Rudnick ◽  
Mia Mazer ◽  
HongQian Wang ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Phase I ◽  
Phase I Trial ◽  
Dendritic Cell Vaccine ◽  
Cell Vaccine ◽  
Newly Diagnosed ◽  
Newly Diagnosed Glioblastoma

EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 2004-2004
Author(s):  
Patrick Roth ◽  
Thierry Gorlia ◽  
Jaap C. Reijneveld ◽  
Filip Yves Francine Leon De Vos ◽  
Ahmed Idbaih ◽  
...  
Keyword(s):  
Standard Therapy ◽  
Standard Treatment ◽  
Early Stage ◽  
Karnofsky Performance Status ◽  
Methylation Status ◽  
Phase Iii ◽  
Newly Diagnosed ◽  
Phase 3 ◽  
Newly Diagnosed Glioblastoma ◽  
Secondary Endpoints

2004 Background: Patients with newly diagnosed glioblastoma receive postoperative standard therapy with radiotherapy (RT), and concomitant and up to six cycles of maintenance temozolomide (TMZ) chemotherapy (TMZ/RT→TMZ). Marizomib is a novel, irreversible and brain-penetrant pan-proteasome inhibitor with encouraging findings in preclinical models and early-stage clinical trials for patients with newly diagnosed and recurrent glioblastoma. Therefore, a phase 3 trial was designed to explore the activity of marizomib in addition to TMZ/RT→TMZ. ClinicalTrials.gov Identifier: NCT03345095 Methods: EORTC 1709/CCTG CE.8 is a multicenter, randomized, controlled, open label phase 3 superiority trial. Eligibility criteria included histologically confirmed newly diagnosed glioblastoma and a Karnofsky performance status (KPS) > 70. Eligible patients were stratified for institution, age, KPS as well as extent of surgery, and centrally randomized in a 1:1 ratio. The primary objective of this study is to compare overall survival (OS) in patients receiving marizomib in addition to standard treatment with patients receiving standard treatment only. Secondary endpoints include progression-free survival (PFS), safety, neurocognitive function, and quality of life. Results: The study was opened at 49 EORTC sites in Europe, 23 CCTG sites in Canada, and 8 sites in the US. Patient enrolment started in June 2018 and was close to completion at the time of a planned interim analysis in September 2020. A total of 749 patients (of the planned 750) were randomized when the IDMC recommended to discontinue enrollment. Age, KPS and extent of resection were well balanced between the 2 study arms. No difference in median OS was observed between the standard arm (15.9 months) and the marizomib arm (15.7 months; HR = 0.99). Median PFS was 6.1 vs. 6.2 months (HR = 1.02). Patients in the marizomib group had more often grade 3/4 treatment-emergent adverse events (TEAE) compared to the standard therapy group (42.6% vs. 20.5%), including ataxia, hallucinations and headache. Conclusions: The addition of marizomib to standard radiochemotherapy did not improve OS or PFS in patients with newly diagnosed glioblastoma. Final survival analyses including determination of MGMT promoter methylation status and analyses of other secondary endpoints are ongoing. Clinical trial information: NCT03345095.

scholarly journals IMMU-13. PD-L1 EXPRESSION PREDICTS SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS RECEIVING VACCINE IMMUNOTHERAPY BUT NOT STANDARD THERAPY ALONE

2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi115-vi115
Author(s):  
Joseph DiDomenico ◽  
Dorina Veliceasa ◽  
Winward Choy ◽  
Daniel Oyon ◽  
Jonathan Lamano ◽  
...  
Keyword(s):  
Standard Therapy ◽  
Newly Diagnosed ◽  
Newly Diagnosed Glioblastoma

scholarly journals P02.01 * MRI ASSESSMENT OF TUMOR SIZE IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED WITH DENDRITIC CELL IMMUNOTHERAPY

2014 ◽  
Vol 16 (suppl 2) ◽  
pp. ii32-ii32
Author(s):  
V. Cuccarini ◽  
C. Schettino ◽  
D. Acquino ◽  
A. Scotti ◽  
L. Cuppini ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Tumor Size ◽  
Newly Diagnosed ◽  
Cell Immunotherapy ◽  
Newly Diagnosed Glioblastoma
Sign in / Sign up

Export Citation Format

Share Document